IMVTHealthcare · BiotechnologyThe 16 Wall Street analysts covering Immunovant, Inc. hold a median 12-month price target of $49 — +12.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 41 of 100 as at 22 Aug 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores Immunovant, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (97): The shares have been drifting up relative to others.
Revisions (30): Analysts have, on balance, been cutting their forecasts.
Size (17): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on IMVT, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +12.0% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 4 Aug 2026 | JP Morgan | Maintains | Overweight | $47 → $50 |
| 30 June 2026 | Citigroup | Maintains | Buy | $57 → $61 |
| 30 June 2026 | Citigroup | Maintains | Buy | — |
| 26 May 2026 | Guggenheim | Maintains | Buy | — |
| 22 May 2026 | Truist Securities | Maintains | Hold | — |
| 21 May 2026 | B of A Securities | Maintains | Buy | — |
| 21 May 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 15 Apr 2026 | Goldman Sachs | Maintains | Neutral | — |
| 20 Mar 2026 | Bernstein | Initiates | Market Perform | — |
| 10 Feb 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 9 Feb 2026 | Guggenheim | Maintains | Buy | — |
| 8 Jan 2026 | Truist Securities | Maintains | Hold | — |
| 6 Jan 2026 | Wolfe Research | Upgrade | Outperform | — |
| 15 Dec 2025 | Goldman Sachs | Maintains | Neutral | — |
| 14 Oct 2025 | Truist Securities | Initiates | Hold | — |
| 30 Sept 2025 | JP Morgan | Maintains | Overweight | — |
| 4 Sept 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 12 Aug 2025 | B of A Securities | Maintains | Buy | — |
| 12 Aug 2025 | JP Morgan | Maintains | Overweight | — |
| 28 July 2025 | UBS | Maintains | Neutral | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. IMVT appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 24 Aug 2026, Immunovant, Inc. returned +184.3% against +19.6% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 95% of US stocks
Cheaper than 8% of US stocks
Cheaper than 86% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 16% of US stocks
Higher than 9% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Immunovant, Inc. has a market value of $8.9B and an enterprise value of $8.2B.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$538.2M.
Diluted earnings per share, trailing twelve months: $−2.82.
Free cash flow in the twelve months to 30 June 2026: −$414.3M.
Trailing P/E: −15.6×; forward P/E: −15.8× — the forward figure prices analyst consensus estimates, not reported earnings.
Immunovant, Inc. employs 315 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Immunovant, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Seeking Alpha published a transcript of Immunovant, Inc.'s Q1 2027 earnings call, covering the company's first-quarter results and management discussion. The item is the call transcript itself rather than an analysis of the results.
Why it matters — An IMVT watcher would care because the earnings call transcript contains the company's own commentary on its quarterly performance and outlook.
Roivant characterized its first quarter as operationally quiet but said it positioned the company for a more active second half of 2026. It cited a potential launch of brepocitinib in dermatomyositis, multiple clinical readouts, and further updates from Immunovant (IMVT).
Why it matters — IMVT watchers would care because the company is flagged for multiple upcoming clinical readouts and further updates later in 2026.
Immunovant reported a wider-than-expected first-quarter loss, driven by increased research and development spending. The company's cash runway is sufficient to support its lead candidate IMVT-1402 through a planned commercial launch for Graves' disease, and its pipeline remains in progress.
Why it matters — Investors would care about whether Immunovant's financial position can fund IMVT-1402 through its planned Graves' disease commercial launch despite the larger quarterly loss.
Immunovant reported financial results for the quarter ended June 30, 2026, and provided corporate updates. The company stated that all IMVT-1402 clinical development timelines remain on track across several indications, and that its current cash balance provides runway to the potential launch of IMVT-1402 in Graves' disease. A live conference call and webcast is scheduled for August 6, 2026.
Why it matters — IMVT watchers would care because the company reaffirmed that its lead candidate IMVT-1402 remains on schedule across multiple programs and that its cash position supports reaching a potential Graves' disease launch.
Seeking Alpha initiated coverage of Immunovant with a BUY rating and $50 price target, citing optimism around IMVT-1402's differentiated profile including strong IgG reduction with minimal albumin and LDL impact, with Graves' disease as the principal valuation driver.
Why it matters — An analyst's positive initiation with a $50 price target and best-in-class potential for IMVT-1402 could influence investor perception of Immunovant's key pipeline asset.
The 16 Wall Street analysts covering Immunovant, Inc. have a median 12-month price target of $49, with estimates ranging from $30 to $66. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 16 analysts covering Immunovant, Inc., 12 rate it a Buy, 4 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Immunovant, Inc. 41 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, Immunovant, Inc. ranks 41 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (97 of 100).
No one can know that. What the data says: the median 12-month target from 16 analysts implies +12.0% from the last close, and Ticker Nerd's factor model ranks Immunovant, Inc. 41 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Immunovant, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IMVT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $30 to $66 over the next 12 months.
Immunovant, Inc. returned +184.3% over the 12 months to 24 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Immunovant Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for autoimmune diseases.
The most recent item we track (Seeking Alpha, 6 Aug 2026): "Immunovant, Inc. (IMVT) Q1 2027 Earnings Call Transcript". Seeking Alpha published a transcript of Immunovant, Inc.'s Q1 2027 earnings call, covering the company's first-quarter results and management discussion. The item is the call transcript itself rather than an analysis of the results.
Immunovant Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for autoimmune diseases. Headquartered in Durham, North Carolina and founded in 2018, the company specializes in immunology and leverages anti-FcRn (neonatal Fc receptor) technology to modulate immunoglobulin G (IgG) levels in the body. Its pipeline includes investigational monoclonal antibody candidates such as batoclimab and IMVT-1402, designed to selectively target FcRn and potentially address a range of autoimmune conditions driven by pathogenic antibodies. Immunovant concentrates on creating targeted, subcutaneous treatments that can be administered in outpatient settings, aiming to provide options that fit into patients’ daily lives. Within the healthcare and biotechnology sector, Immunovant plays a role as an innovator in FcRn inhibition, collaborating closely with clinicians, regulators, and research partners to advance its clinical programs and generate data across multiple autoimmune indications.
CEO Dr. Eric Venker M.D., Pharm.D. · 315 employees · United States · https://immunovant.com
